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Tolerability and dose-related effects of nebivolol in
elderly patients with heart failure: Data from the Study
of the Effects of Nebivolol Intervention on Outcomes
and Rehospitalisation in Seniors with Heart Failure
(SENIORS) trial
Daniela Dobre, MD, MPH, PhD,a Dirk J. van Veldhuisen, MD, PhD, FACC,b Giacomo Mordenti, PhD,c
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and Marcus D. Flather, MBBS, MRCP,f,g on behalf of the SENIORS Investigators Groningen, The Netherlands;
Florence, Italy; Bucharest, Romania; Sydney, Australia; and London, UKBackground The SENIORS trial showed that nebivolol reduced the risk of death or cardiovascular (CV)
hospitalization in elderly patients with heart failure (HF). We aimed to assess tolerability and dose-related effects of the
h-blocker nebivolol in elderly patients from the SENIORS trial.
Methods Patients assigned to nebivolol (n = 1031) were classified into 4 groups, according to the dose achieved at the
end of titration phase (maintenance dose): 0 mg (n = 74), low dose (1.25 or 2.5 mg, n = 142), medium dose (5 mg, n =
127), and target dose (10 mg, n = 688) and compared with those allocated to placebo (n = 1030). Age, sex and ejection
fraction were similar between the groups, but prior myocardial infarction, coronary revascularization, and serum creatinine
levels were lower in patients who achieved higher maintenance doses of nebivolol.
Results After adjustment, all-cause mortality or CV hospitalization was significantly reduced in the 10 mg dose group
compared with placebo (hazard ratio [HR] 0.75, 95% CI 0.63-0.90) which was similar to the medium dose group (HR 0.73,
95% CI 0.52-1.02). The low dose group had an apparently lower benefit (HR 0.88, 95% CI 0.64-1.20), whereas patients
unable to tolerate any dose of nebivolol had an increased risk of death or CV hospitalization (HR 1.95, 95% CI 1.38-2.75).
Conclusions The benefits of nebivolol in elderly patients with HF appear to be related to the maintenance dose
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doi:10.1016/j.ahj.2007.03.025Heart failure (HF) is a major public health problem
among the elderly. In Europe, 6% to 10% of people
N65 years of age have HF, and the average age of the
patient in the community is 76 years.1-3 The syndrome
of HF may arise in presence of either a depressed or
apparently normal left ventricular ejection fraction
(LVEF).4 In older patients, HF with preserved LVEF is
more common than in younger patients.5,6
In elderly patients with HF, the prescription of a
h-blocker raises concerns about tolerability and efficacy.
Recent data suggest that h-blockers are well tolerated in
the elderly,7 yet target doses may be difficult to achieve
in certain subgroups, such as patients with low blood
pressure (BP) and those with advanced disease.8-10 In
turn, prescription of low doses may raise concerns over
efficacy because older patients may respond differently
to medication.11
In patients withHF, one randomized trial has shown that
h-blockade produces a dose-dependent improvement in








dose (n = 74)
Low dose
(1.25 + 2.5 mg)
(n = 142)
Medium dose
(5 mg) (n = 127)
High dose
(10 mg) (n = 688)
Demographics and major baseline characteristics
Age (y) 76 F 4.5 76.7 F 5.1 76.6 F 4.9 76.9 F 4.9 75.7 F 4.5 .002
Sex (women) (%) 35.6 40.5 35.2 29.1 40.7 .09
NYHA (III + IV) (%) 41.1 45.9 40.1 40.9 39.7 .47
LVEF (%) 36.2 F 12.1 34.9 F 14.5 35.7 F 13.0 37.4 F 12.8 35.9 F 12.1 .98
LVEF V35% (%) 64.6 67.6 65.2 63.5 64.1 .68
Heart rate (beat/min) 78.8 F 13.6 76.7 F 12.4 72.8 F 10.1 76.7 F 13.2 81.0 F 13.9 b.001
SBP (mm Hg) 139.8 F 21.1 137.4 F 23.1 134.2 F 20.6 135.3 F 18.6 140.7 F 19.5 b.001
DBP (mm Hg) 80.8 F 11.3 77.7 F 11.2 78.4 F 10.6 78.7 F 11.4 81.8 F 10.5 b.001
Creatinine (Amol/L) 102.7 F 34.2 110.3 F 40.5 107.0 F 39.1 105.3 F 33.6 98.7 F 33.3 b.001
Medical history (%)
Atrial Fibrillation 35.6 29.7 33.8 32.3 33.7 .63
Diabetes 25.0 35.1 31.7 22.8 25.9 .12
Hypertension 62.3 52.7 55.6 57.5 64.7 .004
Myocardial infarct 43.6 56.8 55.6 46.5 40.0 b.001
Prior CABG 8.8 21.6 12.0 10.2 7.8 b.001
Prior PTCA 3.3 9.5 6.3 6.3 2.9 .002
Smoking 5.3 6.8 4.2 6.3 4.5 .49
Medications (%)
ACE Inhibitors 83.3 78.4 85.2 81.9 82.8 .83
Aldosterone
Antagonists
26.0 29.7 35.2 46.5 23.5 b.001
Angiotensin II
Antagonists
8.4 10.8 9.9 7.1 7.6 .29
Antiarrhythmics 18.4 29.7 26.8 17.3 10.9 b.001
Aspirin 51.1 56.8 50.7 54.3 53.5 .99
Ca antagonists 14.5 21.6 12.7 11.0 11.0 .07
Cardiac glycoside 43.0 31.1 38.7 42.5 41.3 .25
Diuretics 85.5 89.2 89.4 88.2 85.3 .11
Lipid-lowering drugs 22.3 29.7 22.5 20.5 20.5 .18
Vitamin K antagonists 24.3 20.3 26.1 16.5 21.7 .93
Data are shown as mean F SD for continuous variables and as percentages for discrete variables. ACE, Angiotensin-converting enzymes.
4Resulting from the logistic regression model having nebivolol dose as response and each baseline characteristic as a covariate.
American Heart Journal
July 2007
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h-blocker trials have not shown a clear dose-response
effect.13,14 The average age of the patients in these trials
was 63 years, and patientswith LVEFN40%were excluded.
The SENIORS trial assessed the effects of the h-blocker
nebivolol in elderly patients (age z70 years) with HF.
About one third of the patients had a preserved LVEF.15
Nebivolol was initiated with a low dose and, if tolerated,
was carefully up-titrated to a target dose of 10 mg daily.
Overall, nebivolol reduced the combined end point of
death or cardiovascular (CV) admission. This outcome
represented an average-dose effect of nebivolol, as the
trial was not designed as a dose-response study. As yet,
there have been no studies relating dose response to
outcome in an elderly population with HF; in this study,
we aimed to assess tolerability and dose-related effects of
nebivolol in patients from the SENIORS trial.Methods
Patients
The study design and main findings of SENIORS have been
published previously.15,16 Briefly, 2128 patients z70 years of
age and with a history of HF were randomly assigned to
nebivolol (1067 patients) or placebo (1061 patients). The initial
dose of nebivolol was 1.25 mg once daily and, if tolerated, was
increased to 2.5 and 5 mg, respectively, every 1 to 2 weeks,
aiming to reach a target of 10 mg once daily over a maximum of
16 weeks. Up-titration could be stopped or delayed depending
on symptoms, side effects, or the judgment of the local
investigator. Overall, nebivolol reduced the combined end
point of death or CV admission compared with placebo (hazard
ratio [HR] 0.86, 95% CI 0.74-0.99, P = .039).
This study includes all those patients who reached a
maintenance dose or who did not tolerate any dose by the
end of titration phase. We analyzed the data by classifying
the patients assigned to nebivolol into 4 groups, according
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4Hazard ratio (95% CI) adjusted for age, sex, heart rate, SBP, DBP, creatinine, hypertension, myocardial infarction, prior CABG, prior PTCA, aldosterone antagonists,
antiarrhythmics and calcium antagonists.
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(maintenance dose): 0 mg (patients who could not tolerate
any dose), low dose (1.25 or 2.5 mg), medium dose (5 mg),
and target dose (10 mg). A total of 67 patients (36 in the
nebivolol group and 31 in the placebo group) were
excluded from this analysis. These were patients who
discontinued the study before the end of titration phase
(16 weeks) despite initial tolerance of study drug. In the
nebivolol group, discontinuation took place because of the
following reasons: patient request (16), death (11), loss to
follow-up (4), adverse event (stroke) (1), hospitalization (2),
and worsening HF (2). In the placebo group, discontinuation
took place as follows: patient request (17), death (9), loss to
follow-up (1), adverse event (myocardial infarction) (1),
patient not taking medication correctly (2), and mandatory
indication for h-blocker (1). Most patients who died during
the titration phase achieved only small doses of nebivolol.
The population of the present study consisted therefore of
1031 patients in the nebivolol group and 1030 patients in
the placebo group.
Clinical outcomes
The primary outcome was the composite of death or CV
hospitalization. Secondary outcomes included the composite of
all-cause mortality or all-cause hospitalization and the com-
posite of CV mortality or CV hospitalization.
Statistical analysis
Logistic regression analysis was used to assess the rela-
tionship between each baseline characteristic and nebivolol
dose groups. The association between dose of nebivolol and
clinical outcomes was assessed using multivariate Cox
proportional hazards models. We controlled for baseline
characteristics that had an independent association with the
dose achieved up to P b .10. Adjustment was performed with
the following variables at baseline: age; sex; heart rate;
systolic BP (SBP); diastolic BP (DBP); creatinine; history of
hypertension; history of myocardial infarction; prior coronary
artery bypass grafting (CABG); prior percutaneous coronary
intervention (PTCA); and prescription of aldosterone antago-
nists, antiarrhythmics, and calcium antagonists. In the Cox
proportional analysis, we compared each dose group with allplacebo patients that reached a maintenance dose or did not
tolerate a maintenance dose (n = 1030). Results are
expressed as HRs with 95% CI. Survival curves were
estimated by the Kaplan-Meier method. Statistical analysis
was performed by using SAS software (version 9.1, SAS
Institute, Cary, NC).Results
Baseline patient characteristics
Patient characteristics at baseline are shown in
Table I. In the nebivolol group (n = 1031), a total of
688 (67%) patients reached the target dose, whereas
127 (12%) and 142 (14%) reached medium and low
doses, respectively. Thus, about 90% of patients were
able to tolerate a dose of nebivolol after the titration
with about 80% achieving doses of z5 mg. A total
of 74 (7%) patients were unable to tolerate a dose
of nebivolol by the end of titration phase. Patients
who only tolerated lower doses were older, had
lower BPs, lower heart rates, and higher creatinine
levels. Patients only tolerating low doses of nebivolol
were also those who had a higher prevalence of
myocardial infarction as the underlying cause of HF,
whereas history of hypertension was more frequent
among those tolerating target doses. No significant
difference was observed across the 4 groups with
regard to LVEF and New York Heart Association
(NYHA) class, but a higher percentage of patients
in NYHA III to IV were unable to tolerate a
maintenance dose. In addition, there was no signifi-
cant difference in associated comorbidities, such as
atrial fibrillation or diabetes. The use of antiarrhyth-
mics and calcium antagonists was higher among
patients tolerating low doses, whereas a similar
proportion received angiotensin-converting enzyme
inhibitors or digitalis.
Approximately 70% of the patients remained on the
same maintenance dose until the end o the study.
Figure 1
Kaplan-Meier survival curves in patients receiving placebo and nebivolol at different maintenance doses. Hazard ratio is given by the multivariate
Cox analysis adjusted for baseline differences.
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In a univariate survival analysis, nebivolol at the target
dose (10 mg) was associated with a significant reduction
of all-cause mortality or CV hospitalization compared
with placebo (HR 0.74, 95% CI 0.62-0.88). Nebivolol in
medium (5 mg) and low dose (1.25 or 2.5 mg) was
associated with a nonsignificant benefit (HR 0.81, 95%
CI 0.58-1.13, and HR 0.94, 95% CI 0.69-1.29, respec-
tively). Patients unable to tolerate any dose of nebivolol
had a higher risk of death or CV admission (HR 2.15, 95%
CI 1.55-3.00) compared the placebo group.
After adjustment, nebivolol in target dose remained
associated with a significant reduction of all-cause
mortality or CV hospitalization (HR 0.75, 95%
CI 0.63-0.90) (Table II). The benefit on this composite
measure was due to an improved outcome on both
all-cause mortality and CV hospitalization (HR 0.84,
95% CI 0.65-1.08, and HR 0.76, 95% CI 0.62-0.94,
respectively). Nebivolol in medium dose had a similar
benefit to the target dose on all-cause mortality or
CV hospitalization (HR 0.73, 95% CI 0.52-1.02), whereas
nebivolol in low dose had an apparently lower benefit
(HR 0.88, 95% CI 0.64-1.20). Other adjusted analyses are
presented in Table II and are similar to the findings of the
unadjusted analyses. The proportion of patients who
suffered death or CV admission decreased with an
increasing dose of nebivolol. Similarly, a higher propor-
tion of patients on low doses experienced the composite
secondary outcomes.Figure 1 shows the Kaplan-Meier survival curves in
patients receiving nebivolol at different doses or place-
bo. The beneficial effects of target and medium doses of
nebivolol on primary outcome appeared early after the
end of titration phase and were constant during follow-
up. Patients intolerant to any dose of nebivolol had a
markedly higher risk of death or CV hospitalization
compared with placebo. Similar results were obtained
on secondary outcomes (Table II and Figure 2).
Discussion
The present study shows that nebivolol is well
tolerated in elderly patients with HF, with about 80% of
patients reaching a maintenance dose of z5 mg. Only
7% of patients were unable to tolerate any maintenance
dose of nebivolol. The data show a significant reduction
in the risk of all-cause mortality and CV hospitalization
when the target dose of nebivolol was compared with
placebo. The beneficial effects appeared early after the
beginning of treatment and were constant during follow-
up. The 5 mg dose appeared to have a similar benefit as
the 10 mg dose, whereas low doses achieved no benefit.
However, the numbers of patients in these groups were
too small to allow firm conclusions. An important novel
finding of the present study is that patients unable to
tolerate a maintenance dose of nebivolol had the worst
outcome, with 2 times higher risk of death or CV
hospitalization. Similar results were obtained on sec-
ondary outcomes.
Figure 2
Primary and secondary outcomes (HR with 95% CI) in patients receiving placebo versus nebivolol at different maintenance doses.
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influenced by clinical factors because patients unable
to tolerate high doses had lower SBP and DBPs and
lower heart rates. Further, they were slightly older and
had a higher prevalence of renal dysfunction and
diabetes. It is of note that patients unable to tolerate
any dose did not differ significantly in mean LVEF and
NYHA class, although a higher proportion of NYHA III
to IV patients were included in this group. This finding
agrees with previous data which showed that severity
of HF per se did not predict successful h-blocker
titration in patients with idiopathic dilated cardiomy-
opathy. Instead, that study showed that only low BP
predicted which patients will develop problems during
titration.17 Other studies have also reported pretreat-
ment BP as a predictor of h-blocker tolerability in
patients with HF.7,18-20 Although the tolerability of
nebivolol (as with many drug treatments) may be
dependent on a more favorable clinical profile, it is
also possible that physicians were more likely to
withhold the treatment if side effects occurred in
bsickerQ patients. Our data show that given the
markedly increased risk on all outcomes in these
patients, increased efforts should be made to initiate
and maintain h-blocker therapy wherever possible in
elderly patients with HF.21
Current European guidelines on HF treatment recom-
mend initiation of h-blocker therapy with a small dose,and a gradual increase in dosage until target dose used in
large clinical trials is achieved.22 However, for obvious
reasons most randomized controlled trials with h-block-
ers in HF were not designed as dose-response studies. To
date, only the MOCHA trial, a relatively small, 6-month
study was designed to evaluate the dose-related effects of
carvedilol in patients with mild to moderate HF.12 The
study found a dose-related improvement in mortality and
LVEF which broadly supports our findings on dose and
clinical outcomes. In contrast to these findings, however,
are subgroup analyses from both MERIT-HF and CIBIS II
trials, which did not show a dose-response effect of
metoprolol and bisoprolol on survival when compared
with placebo.13,14 However, it is difficult to examine
from such post hoc analyses a true dose-response
effect because sicker patients have higher levels of
adrenergic activation,23 and in such patients, lower
h-blocker doses may already be sufficient to achieve a
significant benefit. One other study in which the dose-
response relation was examined was the COMET trial.
This study showed a greater benefit of target versus
subtarget doses of h-blockers, but these subtarget doses
included patients on both medium and low doses.24 In
most of these trials, the mean age of the patients was
much lower than in SENIORS (63 compared with
75 years), and patients with LVEF N40% were excluded.
Data from observational studies, which included
patients with a broad range of LVEF, may be even
American Heart Journal
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Two such studies found a similar benefit on survival
with prescription of high- and low-dose h-blocker
therapy.25,26 In contrast, in the EuroHeart Failure
Survey patients who were treated with high doses of
h-blockers achieved a higher benefit than patients
treated with low doses, but the biases in these
analyses are likely to be larger than in our analysis.27
In a cohort of patients with advanced HF and
preserved LVEF, a higher benefit of high-dose versus
low-dose h-blocker therapy was also observed.28
However, in observational studies, high dose was
defined as z50% of target dose achieved in random-
ized controlled trials, and therefore, no clear distinc-
tion between the effect of target-, medium-, and low-
dose therapy was made. The results of these studies
suggest that patients who achieve at least bmediumQ
doses do better than those on blowerQ doses, although
there are no widely accepted definitions for these
terms. Compared to the randomized trial setting,
which use careful up-titration schedules to reach target
doses, in clinical practice, a lower percentage of
patients may actually receive target doses, and many
patients only receive medium or low doses.28 The
important finding of the present study is that medium
doses of 5 mg nebivolol may be effective in an elderly
HF population.
A high proportion of patients (67%) reached the target
dose of nebivolol in the SENIORS trial. Nebivolol is a h1-
selective blocker whose mechanism of action combines
h-adrenergic blocking activity with vasodilating proper-
ties mediated by nitric oxide modulation on endothelial
cells.29,30 This seemingly good tolerability of nebivolol
may be related to its vasodilating properties.
Our study has a number of limitations. First, because
it is a post hoc analysis, patients were not randomized
to receive different doses of nebivolol, and the dose
prescribed was influenced by patients’ characteristics
and physicians’ decisions. Thus, the comparison
between nebivolol-treated and control patients may
have a number of biases. Second, medium- and low-
dose groups included a small number of patients, and
the analysis may have lacked the power to demon-
strate a statistically significant effect. Third, there was
some overlap on the maintenance doses of medication
during follow-up, as well as a crossover in therapy that
might have influenced the results. Finally, we assessed
only composite outcomes as primary and secondary
end points because the number of events in medium
and low-dose nebivolol groups was too small for
appropriate analysis of simple outcomes.
In conclusion, our analysis indicates that higher
doses of nebivolol (medium to target) appear to give
better results than lower doses. Nebivolol is also well
tolerated in elderly patients with HF. Future random-
ized studies prospectively addressing the issue of doseand outcome are needed in a wide range of thera-
peutic areas.
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